GLP-1 use linked to lower breast cancer incidence in large cohort study
Research Spotlight
GLP-1 use linked to lower breast cancer incidence in large cohort study
A new study from researchers at the University of Pennsylvania is generating excitement in both the breast imaging and oncology communities. Investigators analyzed health records from more than 111,000 women between the ages of 45 and 80 and found that women taking GLP-1 medications—such as Ozempic®, Wegovy®, Mounjaro®, and Zepbound®—were approximately 30% less likely to develop breast cancer compared to women who were not taking these medications.
GLP-1 medications were originally developed to treat type 2 diabetes and are now widely used for weight management. Researchers believe the potential protective effect may extend beyond weight loss alone. These medications have been shown to reduce inflammation, improve metabolic health, and influence biological pathways associated with cancer development.
Importantly, this was an observational study, meaning it found an association but did not prove that GLP-1 medications directly prevent breast cancer. Additional clinical trials are already being planned to determine whether these medications could play a future role in breast cancer prevention, particularly for women at elevated risk.
What This Means for Patients
While these findings are promising, GLP-1 medications are not currently approved for breast cancer prevention. Maintaining a healthy weight, staying physically active, limiting alcohol intake, and following recommended breast cancer screening guidelines remain the most effective ways to reduce risk and support early detection.
As research continues, studies like this may help uncover new strategies to lower breast cancer risk and improve long-term outcomes for women.
Bottom Line: Women taking GLP-1 medications in this study had a significantly lower incidence of breast cancer, but more research is needed before these medications can be recommended as a preventive therapy.
Reference